Therapies based on GLP-1 receptor agonists and DPP-4 inhibitors have a series of benefits compared to conventional therapies for type 2 diabetes mellitus (DM2). Several new agents of this class of drugs have been approved in recent years and are now in clinical practice. In this transmission, Jaime Davidson, MD, presents an overview of recent developments with the use of incretin-based therapies for the treatment of DM2.
Earn CME / CE credit here –
Video credits to ProjectsInKnowledge YouTube channel